To address these shortcomings, we introduce SymPcNSGA-Testing (Symbolic execution, Path clustering and NSGA-II Testing), a ...

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, ...

Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 programMELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex ...

Revenues for year 2025 were RMB802.6 million, representing a year-over-year increase of 201.2%. Net profit for year 2025 ...

Q4 2025 earnings call: 10% organic revenue growth, EBITDA surge, DealMaker partnership and AI “Dolphin Intelligence”—read now.

The second trend also contributing to the future acceleration in digitalization is the upcoming rollout of e-invoicing rules across Europe with regulatory deadlines now clearly in sight, notably in ...

Incannex Healthcare Inc. (NASDAQ:IXHL) on Thursday detailed an updated clinical development plan for IHL-42X, its oral ...

G Mining Ventures Corp. (“GMIN ” or the “Corporation ”) (TSX:GMIN, OTCQX:GMINF) today reported its financial and operating ...

Recent developments in AI make this clear: an AI system with intelligence but without integrity is structurally unfit for ...

APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including:- 75% and 85% ...

Part three of this three-part series on justifying improved control via economics shows how simulation can quantify reduced variation from better control, and how to assess ...

A new column examines how premium airline capacity can help identify the most promising business aviation corridors from the ...